Core Points - Mr. Li Zhongcheng has submitted his resignation as (i) Co-Company Secretary; (ii) Authorized Representative under the Hong Kong Stock Exchange Listing Rules Section 3.05; and (iii) Representative for receiving legal documents and notifications in Hong Kong, effective from September 26, 2025 [1] - Mr. Wu Dongcheng has been appointed as Co-Company Secretary, Authorized Representative, and Legal Process Agent, effective from September 26, 2025 [1] - Ms. Li Lingmei will continue to serve as another Co-Company Secretary [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Medtide Inc. 泰 德 醫 藥（ 浙 江 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 及 豁免嚴格遵守上市規則第3.28條及第8.17條 泰德醫藥（浙江）股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈，李忠成先生（「李先生」）已提出辭任(i)本公司聯席公司秘書（「聯席公司秘 書」）；(ii)香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 3.05條項下之授權代表（「授權代表」）；及(iii)根據上市規則第19A.13(2)條及香港 法例第622章公司條例第16部所規定代表本公司於香港接收法律程序文件及通知 之代表（「法律程序代理人」），自2025年9月26日起生效。 李先生確認彼與董事會並無意見分歧，亦無有關彼辭任之事宜須提請本公司股東 或聯交所垂注。 董事會進一步宣佈，李先生辭任後，吳東澄先生（「吳先生」）已獲委任為聯席公司 ...

Financial Performance - Revenue for the first half of 2025 reached RMB 253.8 million, a 28.5% increase from RMB 197.5 million in the same period of 2024[6]. - Gross profit increased by 44.3% to RMB 155.0 million, compared to RMB 107.4 million in the previous year, resulting in a gross margin of 61.1%[6][15]. - Net profit surged by 101.7% to RMB 102.0 million, up from RMB 50.6 million in the prior year, with a net profit margin of 40.2%[6][15]. - Adjusted net profit (non-IFRS measure) increased by 14.9% to RMB 104.1 million from RMB 90.6 million in the previous year[15]. - For the six months ended June 30, 2025, the profit reached RMB 102.0 million, compared to RMB 50.6 million for the same period in 2024, representing a significant increase due to higher gross profit and fair value gains on financial liabilities[47]. - The adjusted net profit for the six months ended June 30, 2025, was RMB 104.1 million, up from RMB 90.6 million in the same period of 2024, reflecting a growth of approximately 15%[48]. - Basic earnings per share for the period was RMB 0.82, compared to RMB 0.40 in 2024, reflecting a 105% increase[96]. - The company reported a total comprehensive income of RMB 101,512,000 for the six months ended June 30, 2025, compared to RMB 50,967,000 in 2024[97]. Operational Highlights - The number of ongoing projects at the end of June 2025 was 1,463, an increase from 1,378 in June 2024[9][11]. - The number of new projects acquired during the first half of 2025 was 4,674, compared to 4,353 in the same period of 2024[9]. - The company expanded its workforce to 520 full-time employees, a 14.5% increase compared to the previous year[7]. - The company has a peptide API production capacity exceeding 500 kg annually, with each batch capable of producing over 30 kg, and can handle multiple orders of 100 kg scale[26]. - The company has 338 ongoing CDMO projects, including nine NCE GLP-1 molecule development projects with seven clients[29]. - The company has passed 17 regulatory and customer audits during the reporting period, demonstrating strong compliance and quality assurance[23]. Market and Industry Insights - The global peptide drug market is projected to grow from $89.5 billion in 2023 to $261.2 billion by 2032, with a compound annual growth rate (CAGR) of 12.6%[28]. - The GLP-1 drug market is expected to grow from $38.9 billion in 2023 to $129.9 billion by 2032, with a CAGR of 14.3%[28]. - The company plans to further develop in the global Tides drug market, particularly in the GLP-1 peptide segment[7]. Financial Position - As of June 30, 2025, the company had cash and cash equivalents of RMB 998.4 million, a substantial increase from RMB 387.2 million as of December 31, 2024, primarily due to operating cash flow and proceeds from a global offering[50]. - The total outstanding borrowings amounted to RMB 50.0 million as of June 30, 2025, with an interest rate ranging from 2.60% to 2.70%[55]. - The company's debt-to-asset ratio improved to 17.1% as of June 30, 2025, down from 72.8% as of December 31, 2024, mainly due to changes in equity and proceeds from the global offering[55]. - The company’s total equity increased to RMB 1,468,903,000 as of June 30, 2025, compared to RMB 318,750,000 at the end of 2024[100]. - The company’s current liabilities totaled RMB 265,349,000 as of June 30, 2025, compared to RMB 172,043,000 at the end of 2024, indicating increased operational activity[99]. Employee and Governance - The company has implemented a high-standard quality management system, with 100 employees in the quality assurance and control department as of June 30, 2025[22]. - The total employee count is 520, with 47% in production, 19% in quality assurance, and 12% in R&D[63]. - The company has adopted a share incentive plan to attract and retain quality employees[63]. - The company maintains a commitment to high standards of corporate governance and has complied with all applicable code provisions since its listing[68]. Future Plans and Investments - The company plans to expand production capacity in the U.S. and China, aiming for an annual capacity of 300 kg in the U.S. and an additional 500 kg in China by the end of 2025[30]. - The company plans to allocate HKD 327.58 million (76.40%) of the net proceeds for expanding service capacity and production through facility construction by December 31, 2026[76]. - The company is preparing for the commercialization of new drugs following regulatory approvals[174]. - The company has plans for market expansion and potential mergers and acquisitions in the future[174]. Regulatory and Compliance - The company received ISO 22716:2007 certification for good manufacturing practices in January 2025[7]. - The independent review report confirms that the interim financial data is prepared in accordance with International Accounting Standard 34[94]. - The company has not identified any matters that would lead to a belief that the interim financial data is not prepared in accordance with the relevant standards[94].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 泰德醫藥（浙江）股份有限公司（「本公司」） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03880 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 73,598,888 | RMB | | 1 RMB | | 73,598,888 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 73,598,888 | RMB | | 1 RMB | | 73,598,888 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].

Core Insights - The company reported a 28.5% increase in revenue to RMB 253.8 million for the six months ending June 30, 2025, with a net profit increase of 101.7% to RMB 102.0 million [1] - The gross profit margin improved to 61.1%, up 6.7 percentage points from 54.4% in the previous year, primarily due to lower growth in sales costs compared to reductions in employee compensation and utility expenses [1] Financial Performance - Revenue increased by 28.5% to RMB 253.8 million [1] - Gross profit rose by 44.3% to RMB 155.0 million [1] - Net profit surged by 101.7% to RMB 102.0 million [1] - Gross margin improved to 61.1% from 54.4% [1] Market Presence - The company has established stable customer relationships in over 50 countries, including major markets such as China, the USA, Japan, Europe, South Korea, and Australia [1] - The company provides peptide drug development, production, and CMC filing support services compliant with global regulatory standards [1] Project Pipeline - The number of ongoing CDMO projects increased from 332 to 338 within a year [1] - The company has a strategic focus on GLP-1 pipeline projects, with 338 ongoing CDMO projects, including nine NCE GLP-1 molecule development projects with seven clients [1] Production Capacity - The company has significant peptide API production capacity, with a cGMP-compliant facility in Hangzhou covering over 20,000 square meters [2] - The annual production capacity for peptide APIs exceeds 500 kg, with batch capacities over 30 kg [2] - The company has initiated expansion projects in Rocklin, California, and Hangzhou, including the installation of 3,000-liter SPPS reactors [2]

Core Insights - The company, 泰德医药 (03880), reported a revenue of 254 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 28.52% [1] - Shareholder profit attributable to the company was 102 million RMB, which is a significant year-on-year increase of 101.71% [1] - Basic earnings per share were reported at 0.82 RMB [1] - The increase in revenue is primarily attributed to the growth in FFS and FTE business segments, driven by increased demand for the company's services [1]

[Interim Results Summary](index=1&type=section&id=%E4%B8%AD%E6%9C%9F%E6%A5%AD%E7%B8%BE%E6%91%98%E8%A6%81) Medtide Pharmaceuticals (Zhejiang) Co., Ltd. announced its unaudited consolidated results for the six months ended June 30, 2025, showing significant growth in revenue, gross profit, profit before tax, and profit for the period Interim Results Summary for the Six Months Ended June 30, 2025 | Indicator | 2025 (RMB thousands) | 2024 (RMB thousands) | Year-on-year Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 253,767 | 197,457 | 28.5% | | Gross Profit | 154,954 | 107,407 | 44.3% | | Gross Margin (%) | 61.1% | 54.4% | - | | Profit Before Tax | 115,677 | 58,512 | 97.7% | | Profit for the Period | 101,999 | 50,567 | 101.7% | | Net Margin (%) | 40.2% | 25.6% | - | [Management Discussion and Analysis](index=2&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%A4%E8%A8%8E%E8%AB%96%E5%8F%8A%E5%88%86%E6%9E%90) This section provides an in-depth analysis of the company's operational performance, strategic initiatives, and financial results for the reporting period [Business Review](index=2&type=section&id=%E6%A5%AD%E5%8B%99%E5%9B%9E%E9%A1%A7) The company maintained business growth in H1 2025, successfully completed its global offering and listing, and expanded its global client relationships and service footprint, particularly in peptide and oligonucleotide CRDMO services [Key Operating Data](index=2&type=section&id=%E9%97%9C%E9%8D%B5%E9%81%8B%E7%87%9F%E6%95%B8%E6%93%9A) During the reporting period, the company maintained growth in the number of ongoing projects, particularly in CRO and CDMO (CMC development phase) projects, reflecting continuous business expansion Key Operating Data | Indicator | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Number of ongoing projects at beginning of period | 1,549 | 1,449 | | Number of new projects obtained during period | 4,674 | 4,353 | | Number of projects completed at end of period | 4,760 | 4,424 | | Number of ongoing projects at end of period | 1,463 | 1,378 | Breakdown of Ongoing Projects at Period End | Project Type | June 30, 2025 | June 30, 2024 | | :--- | :--- | :--- | | CRO | 1,125 | 1,046 | | CDMO (CMC Development Phase) | 325 | 319 | | CDMO (Commercial Manufacturing Phase) | 13 | 13 | | Total | 1,463 | 1,378 | - The company successfully completed its global offering, achieving a listing milestone in **June 2025**[8](index=8&type=chunk) - The company has established stable client relationships and a service footprint in over **50** countries, offering full-lifecycle solutions for peptide synthesis, development, and production[8](index=8&type=chunk) - As of June 30, 2025, full-time employees totaled **520**, a **14.5%** year-on-year increase, to meet growing demand[8](index=8&type=chunk) [Overall Performance of TIDES CRDMO](index=3&type=section&id=TIDES%20CRDMO%E6%95%B4%E9%AB%94%E8%A1%A8%E7%8F%BE) Guided by the 'Molecule-to-Market' strategy, the TIDES CRDMO business continued to grow, with significant increases in revenue, gross profit, and net profit, alongside a steady rise in adjusted net profit TIDES CRDMO Key Financial Indicators | Indicator | Six Months Ended June 30, 2025 (RMB millions) | Six Months Ended June 30, 2024 (RMB millions) | Growth Rate (%) | | :--- | :--- | :--- | :--- | | Revenue | 253.8 | 197.5 | 28.5% | | Gross Profit | 155.0 | 107.4 | 44.3% | | Net Profit | 102.0 | 50.6 | 101.7% | | Adjusted Net Profit (Non-IFRS) | 104.1 | 90.6 | 14.9% | - The number of ongoing CDMO projects increased from **332** as of June 30, 2024, to **338** as of June 30, 2025[13](index=13&type=chunk) [Service Scope and Market Positioning](index=4&type=section&id=%E6%9C%8D%E5%8B%99%E7%AF%84%E5%9C%8D%E8%88%87%E5%B8%82%E5%A0%B4%E5%AE%9A%E4%BD%8D) As a leading global peptide CRDMO, the company offers full-lifecycle services from early discovery to commercial production, primarily focusing on APIs rather than drug products, and strategically expanding into oligonucleotide CDMO services - The company provides CRO services (peptide NCE discovery synthesis) and CDMO services (peptide CMC development and commercial production), primarily offering APIs[14](index=14&type=chunk) - Stable client relationships have been established in over **50** countries, including China, the United States, Japan, Europe, South Korea, and Australia[14](index=14&type=chunk) - Strategically offering oligonucleotide CDMO services to clients, covering preclinical research, clinical development, and commercial production[17](index=17&type=chunk) [Technology Platforms](index=5&type=section&id=%E6%8A%80%E8%A1%93%E5%B9%B3%E5%8F%B0) The company has 61 R&D employees, with approximately 40% holding master's degrees or higher, focusing on strengthening advanced synthesis methods and proprietary technology platforms to maintain a competitive edge - The R&D department comprises **61** employees, with approximately **40%** holding master's degrees or higher[19](index=19&type=chunk) - The company masters advanced synthesis methods including solid-phase synthesis, liquid-phase synthesis, hybrid solid-liquid synthesis, and fragment condensation synthesis[19](index=19&type=chunk) - Proprietary technology platforms include OmniPeptSynth™ (efficient peptide synthesis), PeptiConjuX™ and PeptiNuclide LinkTech™ (custom synthesis of conjugated peptide APIs and radiopharmaceutical conjugates), GreenSynth Innovations™ (green chemistry), and Impurity Screening™ (impurity analysis)[20](index=20&type=chunk)[23](index=23&type=chunk) [Quality Management](index=5&type=section&id=%E8%B3%AA%E9%87%8F%E7%AE%A1%E7%90%86) The company has established a high-standard quality management system with a 100-employee Quality Assurance and Quality Control department, successfully passing multiple domestic and international regulatory and client GMP inspections and audits - The Quality Assurance and Quality Control department has a total of **100** employees[21](index=21&type=chunk) - All client quality audits have been passed in the past five years, along with **five** FDA on-site GMP inspections, **three** other overseas regulatory inspections, and **nine** NMPA inspections[21](index=21&type=chunk) - ISO9001 and ISO13485 certifications have been obtained, and **17** regulatory and client audits were passed during the reporting period[21](index=21&type=chunk)[22](index=22&type=chunk) [Production Capacity](index=6&type=section&id=%E7%94%A2%E8%83%BD) The company possesses substantial peptide API production capacity, with cGMP facilities in Hangzhou Qiantang Park exceeding **500 kg** annual capacity, and new expansion projects initiated, including establishing a production base in Rocklin Park, USA - The cGMP-compliant production facility in Hangzhou Qiantang Park has a total floor area exceeding **20,000** square meters, with an annual peptide API production capacity exceeding **500 kg** and batch capacity exceeding **30 kg**[24](index=24&type=chunk) - The Qiantang Park facility has the capability to produce **1 to 17 kg** of oligonucleotides annually[24](index=24&type=chunk) - As of June 30, 2025, new expansion projects have been initiated at Rocklin Park (California) and Qiantang Park, including the installation of a **3,000-liter** SPPS reactor[24](index=24&type=chunk) [Business Development](index=6&type=section&id=%E6%A5%AD%E5%8B%99%E7%99%BC%E5%B1%95) The company operates sales offices globally, strategically expanding its reach into European and Asian markets, increasing resources for oligonucleotide drug market entry, and continuously growing its client base through industry conferences and client engagement - Sales offices operate globally, with dedicated sales and marketing teams in China, the United States, and Europe[25](index=25&type=chunk) - Strategically expanding business scope into European and Asian markets, and increasing business development resources to enter the oligonucleotide drug market[25](index=25&type=chunk) - Actively participating in industry conferences such as DCAT 2025 and TIDES USA to enhance brand awareness and expand the client base[25](index=25&type=chunk) [Outlook](index=6&type=section&id=%E5%B1%95%E6%9C%9B) The company benefits from strong growth in the GLP-1 receptor agonist market, having established an extensive project pipeline with a particular focus on GLP-1, and plans to capitalize on market opportunities through capacity expansion, technology development, and generic drug pipeline construction [Market Trends and Opportunities](index=6&type=section&id=%E5%B8%82%E5%A0%B4%E8%B6%A8%E5%8B%A2%E8%88%87%E6%A9%9F%E9%81%87) The GLP-1 receptor agonist market has seen significant sales growth, with global peptide and GLP-1 drug markets projected for continued high growth, presenting substantial opportunities for the company - In H1 2025, the GLP-1 receptor agonist market saw significant sales growth, with Novo Nordisk's semaglutide products reaching **USD 16.683 billion** in sales, becoming the world's top-selling drug[26](index=26&type=chunk) - The global peptide drug market is projected to grow from **USD 89.5 billion** in 2023 to **USD 261.2 billion** in 2032, at a CAGR of **12.6%**[26](index=26&type=chunk) - The GLP-1 drug market is expected to grow from **USD 38.9 billion** in 2023 to **USD 129.9 billion** in 2032, at a CAGR of **14.3%**[26](index=26&type=chunk) - As of June 30, 2025, the company's project pipeline includes **338** ongoing CDMO projects, with **nine** NCE GLP-1 molecule development projects conducted with **seven** clients[27](index=27&type=chunk) [Future Strategy and Capacity Expansion](index=7&type=section&id=%E6%9C%AA%E4%BE%86%E6%88%B0%E7%95%A5%E8%88%87%E7%94%A2%E8%83%BD%E6%8B%B6%E5%BC%B5) The company plans capacity expansion in the US and China, expecting a significant increase in annual API production, while continuing to focus on advanced technology development and building a high-value generic drug product pipeline - Equipment installation at Rocklin Park (USA) is planned to commence in H2 2025, aiming for an annual peptide API production capacity of **300 kg**[28](index=28&type=chunk) - The new expansion project at Hangzhou Qiantang Park is expected to be completed by the end of 2025, adding **500 kg** of capacity, bringing Medtide Group's total annual API capacity to over **1,000 kg**[28](index=28&type=chunk) - Plans for the next few years include building or acquiring new production facilities to increase annual API production by several additional metric tons, with batch capacity rising to **100 kg**, to meet GLP-1 product demand[29](index=29&type=chunk) - The "Molecule-to-Market" strategy will be further implemented, with plans for CMC research on novel TIDES-related drugs such as GLP-1, PDC, RDC, and POC[29](index=29&type=chunk) - The company plans to continuously enhance automation in production processes and develop high-value generic drug products, actively preparing for DMF submissions[29](index=29&type=chunk) [Financial Review](index=8&type=section&id=%E8%B2%A1%E5%8B%99%E5%9B%9E%E9%A1%A7) During the reporting period, the company achieved significant growth in revenue, gross profit, and net profit, primarily driven by strong performance in FFS and CDMO businesses, while maintaining ample liquidity and substantially improving its gearing ratio [Revenue](index=8&type=section&id=%E6%94%B6%E7%9B%8A) For the six months ended June 30, 2025, revenue increased by **28.5%** year-over-year, primarily driven by increased demand in FFS and FTE businesses, with particularly significant growth in CDMO service revenue Revenue Breakdown by Charging Model | Charging Model | 2025 (RMB thousands) | 2024 (RMB thousands) | Year-on-year Change (%) | | :--- | :--- | :--- | :--- | | FFS | 232,924 | 192,944 | 20.7% | | FTE | 20,843 | 4,296 | 385.2% | | Others | – | 217 | Not Applicable | | Total | 253,767 | 197,457 | 28.5% | Revenue Breakdown by Service Type | Service Type | 2025 (RMB thousands) | 2024 (RMB thousands) | Year-on-year Change (%) | | :--- | :--- | :--- | :--- | | CRO Services | 55,570 | 47,632 | 16.7% | | CDMO Services | 198,197 | 149,608 | 32.5% | | Others | – | 217 | Not Applicable | | Total | 253,767 | 197,457 | 28.5% | - CDMO revenue grew by **32.5%**, primarily from clients with late-stage clinical or commercial projects[32](index=32&type=chunk) [Cost of Sales](index=9&type=section&id=%E9%8A%B7%E5%94%AE%E6%88%90%E6%9C%AC) Cost of sales increased by **9.7%** year-over-year, primarily due to increased production volume, despite a decrease in staff costs and utility expenses Cost of Sales Breakdown | Item | 2025 (RMB thousands) | 2024 (RMB thousands) | Year-on-year Change (%) | | :--- | :--- | :--- | :--- | | Material Costs | 36,322 | 28,290 | 28.4% | | Staff Costs | 29,987 | 31,672 | -5.3% | | Utilities and Other Expenses | 12,218 | 13,460 | -9.2% | | Depreciation and Amortization | 8,995 | 9,646 | -6.7% | | Share-based Payment Expenses | 951 | 940 | 1.2% | | Others | 10,340 | 6,042 | 71.1% | | Total | 98,813 | 90,050 | 9.7% | [Gross Profit and Gross Margin](index=9&type=section&id=%E6%AF%9B%E5%88%A9%E5%8F%8A%E6%AF%9B%E5%88%A9%E7%8E%87) Gross profit increased by **44.3%** year-over-year, with gross margin improving by **6.7** percentage points to **61.1%**, primarily due to slower growth in cost of sales compared to revenue growth - Gross profit increased from **RMB 107.4 million** to **RMB 155.0 million**, a **44.3%** increase[35](index=35&type=chunk) - Gross margin increased from **54.4%** to **61.1%**, an increase of **6.7** percentage points[35](index=35&type=chunk) [Other Income and Gains](index=9&type=section&id=%E5%85%B6%E4%BB%96%E6%94%B6%E5%85%A5%E5%8F%8A%E6%94%B6%E7%9B%8A) Other income and gains decreased by **60.4%** year-over-year, primarily due to a one-off bond-related subsidy recognized in 2024 - Other income and gains decreased from **RMB 42.9 million** to **RMB 17.0 million**[36](index=36&type=chunk) - The decrease was primarily due to the one-off nature of bond-related subsidies recognized in **2024**[36](index=36&type=chunk) [Selling and Marketing Expenses](index=9&type=section&id=%E9%8A%B7%E5%94%AE%E5%8F%8A%E7%87%9F%E9%8Š%B7%E9%96%8B%E6%94%AF) Selling and marketing expenses increased by **7.5%** year-over-year, consistent with increased client-related activities and sales revenue growth - Selling and marketing expenses increased from **RMB 17.3 million** to **RMB 18.6 million**, a **7.5%** increase[37](index=37&type=chunk) [Administrative Expenses](index=10&type=section&id=%E8%A1%8C%E6%94%BF%E9%96%8B%E6%94%AF) Administrative expenses increased by **5.7%** year-over-year, primarily due to higher listing expenses - Administrative expenses increased from **RMB 38.3 million** to **RMB 40.5 million**, a **5.7%** increase[38](index=38&type=chunk) [Research and Development Expenses](index=10&type=section&id=%E7%A0%94%E7%99%BC%E9%96%8B%E6%94%AF) Research and development expenses decreased by **2.3%** year-over-year, primarily due to reduced material costs - Research and development expenses decreased from **RMB 13.0 million** to **RMB 12.7 million**, a **2.3%** decrease[39](index=39&type=chunk) [Income Tax Expense](index=10&type=section&id=%E6%89%80%E5%BE%97%E7%A8%85%E9%96%8B%E6%94%AF) Income tax expense significantly increased year-over-year, comprising both current and deferred tax components - Income tax expense increased from **RMB 7.9 million** to **RMB 13.7 million**[40](index=40&type=chunk) [Fair Value Gain/(Loss) on Financial Liabilities at Fair Value Through Profit or Loss](index=10&type=section&id=%E6%8C%89%E5%85%AC%E5%85%81%E5%83%B9%E5%80%BC%E8%A8%88%E5%85%A5%E6%90%8D%E7%9B%8A%E7%9A%84%E9%87%91%E8%9E%8D%E8%B2%A0%E5%82%B5%E7%9A%84%E5%85%AC%E5%85%81%E5%83%B9%E5%80%BC%E6%94%B6%E7%9B%8A%E2%88%95%EF%BC%88%E虧%E6%90%8D%EF%BC%89) This item shifted from a loss in 2024 to a gain in 2025, primarily due to changes in the company's valuation - Shifted from a loss of **RMB 21.7 million** in 2024 to a gain of **RMB 18.5 million** in 2025[41](index=41&type=chunk) [Profit for the Period](index=10&type=section&id=%E6%9C%9F%E5%85%A7%E5%88%A9%E6%BD%A4) Profit for the period increased by **101.7%** year-over-year, primarily driven by higher gross profit and fair value gains on financial liabilities at fair value through profit or loss - Profit for the period increased from **RMB 50.6 million** to **RMB 102.0 million**, a **101.7%** increase[42](index=42&type=chunk) [Non-IFRS Measures](index=10&type=section&id=%E9%9D%9E%E5%9C%8B%E9%9A%9B%E8%B2%A1%E5%8B%99%E5%A0%B1%E5%91%8A%E6%BA%96%E5%89%87%E8%A8%88%E9%87%8F) The company uses adjusted net profit as a supplementary financial measure to provide a clearer perspective on operating performance, which showed growth during the reporting period - Adjusted net profit (Non-IFRS measure) is defined as profit for the period adjusted for fair value gain/loss on financial liabilities, share-based payment expenses, and listing expenses[43](index=43&type=chunk) Reconciliation of Profit to Adjusted Net Profit | Item | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Profit for the Period | 101,999 | 50,567 | | Add back: Fair value (gain)/loss on financial liabilities at fair value through profit or loss | (18,463) | 21,683 | | Add back: Share-based payment expenses | 2,311 | 2,132 | | Add back: Listing expenses | 18,211 | 16,183 | | Adjusted Net Profit for the Period (Non-IFRS measure) | 104,058 | 90,565 | [Liquidity and Capital Resources](index=11&type=section&id=%E6%B5%81%E5%8B%95%E8%B3%87%E9%87%91%E5%8F%8A%E8%B3%87%E6%9C%AC%E8%B3%87%E6%BA%90) The company maintains ample liquidity, with a significant increase in cash and cash equivalents, primarily due to cash generated from operations and proceeds from the global offering - As of June 30, 2025, cash and cash equivalents significantly increased to **RMB 998.4 million** from **RMB 387.2 million** as of December 31, 2024[45](index=45&type=chunk) - Primary sources of liquidity include cash generated from operations, capital contributions from shareholders, and proceeds from the issuance of equity shares (global offering)[45](index=45&type=chunk) [Material Investments](index=11&type=section&id=%E9%87%8D%E5%A4%A7%E6%8A%95%E8%B3%87) During the reporting period, the company did not make or hold any material investments - For the six months ended June 30, 2025, the company did not make or hold any material investments[46](index=46&type=chunk) [Material Acquisitions and/or Disposals of Subsidiaries, Associates and Joint Ventures](index=11&type=section&id=%E9%99%84%E5%B1%AC%E5%85%AC%E5%8F%B8%E3%80%81%E8%81%AF%E7%87%9F%E5%85%AC%E5%8F%B8%E5%8F%8A%E5%90%88%E8%B3%87%E4%BC%81%E6%A5%AD%E7%9A%84%E9%87%8D%E5%A4%A7%E6%94%B6%E8%B3%BC%E5%8F%8A%E2%88%95%E6%88%96%E5%87%BA%E5%94%AE) During the reporting period, the company did not undertake any material acquisitions and/or disposals of subsidiaries and associates - For the six months ended June 30, 2025, the company did not undertake any material acquisitions and/or disposals of subsidiaries and associates[47](index=47&type=chunk) [Future Plans for Material Investments and Capital Assets](index=12&type=section&id=%E9%87%8D%E5%A4%A7%E6%8A%95%E8%B3%87%E5%8F%8A%E8%B3%87%E6%9C%AC%E8%B3%87%E7%94%A2%E7%9A%84%E6%9C%AA%E4%BE%86%E8%A8%88%E5%8A%83) Except as disclosed in the prospectus and this announcement, the company has no other future plans for material investments or capital assets - As of June 30, 2025, the Group had no future plans for material investments or capital assets other than those disclosed in the prospectus and this announcement[48](index=48&type=chunk) [Employees and Remuneration](index=12&type=section&id=%E5%83%B1%E5%93%A1%E5%8F%8A%E8%96%AA%E9%85%AC) The company's employee headcount increased, leading to a corresponding rise in total employee benefit expenses - As of June 30, 2025, the number of full-time employees was **520**, an increase from **454** as of June 30, 2024[49](index=49&type=chunk) - Total employee benefit expenses (including share-based payment expenses) increased from **RMB 64.4 million** to **RMB 71.1 million**[49](index=49&type=chunk) [Bank Borrowings and Gearing Ratio](index=12&type=section&id=%E9%8A%80%E8%A1%8C%E5%80%9F%E6%AC%BE%E5%8F%8A%E8%B3%87%E7%94%A2%E8%B2%A0%E5%80%B5%E6%AF%94%E7%8E%87) The company's outstanding borrowings remained low, and the gearing ratio significantly decreased due to changes in redeemable equity shares liability and proceeds from the global offering - As of June 30, 2025, outstanding borrowings amounted to **RMB 50.0 million**[50](index=50&type=chunk) - The gearing ratio significantly decreased from **72.8%** as of December 31, 2024, to **17.1%** as of June 30, 2025[50](index=50&type=chunk) [Contingent Liabilities](index=12&type=section&id=%E6%88%96%E7%84%B6%E8%B2%A0%E5%82%B5) As of the end of the reporting period, the company had no material contingent liabilities or guarantees - As of June 30, 2025, the company had no material contingent liabilities or guarantees[51](index=51&type=chunk) [Pledge of Assets](index=12&type=section&id=%E8%B3%87%E7%94%A2%E8%B3%AA%E6%8A%BC) As of the end of the reporting period, the company had not pledged or charged any assets, except for restricted cash - As of June 30, 2025, the company had not pledged or charged any other assets, except for restricted cash used as collateral for foreign exchange transactions and other operating activities[52](index=52&type=chunk) [Foreign Exchange Risk](index=12&type=section&id=%E5%A4%96%E5%8C%AF%E9%A2%A8%E9%9A%AA) The company faces foreign exchange risk, but no hedging was undertaken during the reporting period due to the expected immateriality of the risk, and it will continue to be monitored - The company faces foreign exchange risk related to the US Dollar, Hong Kong Dollar, and Euro[53](index=53&type=chunk) - For the six months ended June 30, 2025, the Group did not use any financial instruments for hedging purposes, as the expected exchange rate risk was not material[53](index=53&type=chunk) [Interim Condensed Consolidated Statement of Profit or Loss](index=13&type=section&id=%E4%B8%AD%E6%9C%9F%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E6%90%8D%E7%9B%8A%E8%A1%A8) This section presents the unaudited consolidated statement of profit or loss for the six months ended June 30, 2025, detailing the company's financial performance including revenue, costs, expenses, and profit for the period - The statement of profit or loss includes revenue, cost of sales, gross profit, other income and gains, various expenses, finance costs, fair value changes, and income tax expense[55](index=55&type=chunk) - Profit for the period was **RMB 101,999 thousand** (2024: **RMB 50,567 thousand**)[55](index=55&type=chunk) - Basic earnings per share were **RMB 0.82** (2024: **RMB 0.40**), and diluted earnings per share were **RMB 0.82** (2024: **RMB 0.30**)[55](index=55&type=chunk) [Interim Condensed Consolidated Statement of Comprehensive Income](index=14&type=section&id=%E4%B8%AD%E6%9C%9F%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E5%85%A8%E9%9D%A2%E6%94%B6%E7%9B%8A%E8%A1%A8) This section presents the unaudited consolidated statement of comprehensive income for the six months ended June 30, 2025, including profit for the period and other comprehensive income items such as exchange differences on translation of foreign operations - Profit for the period was **RMB 101,999 thousand** (2024: **RMB 50,567 thousand**)[57](index=57&type=chunk) - Exchange differences on translation of foreign operations amounted to **RMB (487) thousand** (2024: **RMB 400 thousand**)[57](index=57&type=chunk) - Total comprehensive income for the period was **RMB 101,512 thousand** (2024: **RMB 50,967 thousand**)[57](index=57&type=chunk) [Interim Consolidated Statement of Financial Position](index=15&type=section&id=%E4%B8%AD%E6%9C%9F%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E7%8B%80%E6%B3%81%E8%A1%A8) This section provides the unaudited consolidated statement of financial position as of June 30, 2025, detailing the company's assets, liabilities, and equity composition - Total non-current assets were **RMB 487,486 thousand** (December 31, 2024: **RMB 478,828 thousand**)[58](index=58&type=chunk) - Total current assets were **RMB 1,284,001 thousand** (December 31, 2024: **RMB 693,800 thousand**), including cash and cash equivalents of **RMB 998,403 thousand**[58](index=58&type=chunk) - Total current liabilities were **RMB 265,349 thousand** (December 31, 2024: **RMB 172,043 thousand**)[58](index=58&type=chunk) - Total non-current liabilities were **RMB 37,235 thousand** (December 31, 2024: **RMB 681,835 thousand**), with redeemable equity shares liability reduced to zero[59](index=59&type=chunk) - Total equity was **RMB 1,468,903 thousand** (December 31, 2024: **RMB 318,750 thousand**)[59](index=59&type=chunk) [Notes to the Interim Condensed Consolidated Financial Information](index=17&type=section&id=%E4%B8%AD%E6%9C%9F%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E8%B3%87%E6%96%99%E9%99%84%E8%A8%BB) This section provides detailed explanatory notes to the interim condensed consolidated financial information, covering company details, basis of preparation, accounting policy changes, and segment information [Company Information](index=17&type=section&id=%E5%85%AC%E5%8F%B8%E8%B3%87%E6%96%99) Medtide Pharmaceuticals (Zhejiang) Co., Ltd. was established in 2020, restructured as a joint-stock company in 2023, and primarily provides CRDMO services for peptide production - The company was established in China as a limited liability company on **June 11, 2020**, and restructured into a joint-stock company on **February 10, 2023**[60](index=60&type=chunk) - Its principal activities involve providing significant Contract Research, Development and Manufacturing Organization (CRDMO) services, focusing on synthetic peptide production[60](index=60&type=chunk) [Basis of Preparation](index=17&type=section&id=%E7%B7%A8%E8%A3%BD%E5%9F%BA%E6%BA%96) The interim condensed consolidated financial information is prepared in accordance with IAS 34 and presented in RMB, and should be read in conjunction with the company's prospectus - The interim condensed consolidated financial information is prepared in accordance with International Accounting Standard **34** Interim Financial Reporting[61](index=61&type=chunk) - The financial information is presented in **RMB**, with all values rounded to the nearest thousand[61](index=61&type=chunk) [Changes in Accounting Policies](index=17&type=section&id=%E6%9C%83%E8%A8%88%E6%94%BF%E7%AD%96%E8%AE%8A%E5%8B%95) Accounting policies adopted this period are consistent with the prior year, with only IAS 21 (Amendment) 'Lack of Exchangeability' being newly adopted, which had no material impact on the Group's financial information - The financial information for this period saw the first-time adoption of IAS **21** (Amendment) 'Lack of Exchangeability'[62](index=62&type=chunk)[63](index=63&type=chunk) - This amendment had no impact on the interim condensed consolidated financial information, as all the Group's transaction currencies are convertible[63](index=63&type=chunk) [Segment Information](index=17&type=section&id=%E5%88%86%E9%83%A8%E8%B3%87%E6%96%99) The company operates in a single reportable segment, providing external customer revenue and non-current asset information by geographical location, along with revenue contributions from major clients - The Group has only one reportable segment, with the CEO reviewing consolidated results to allocate resources and assess overall performance[64](index=64&type=chunk) External Customer Revenue by Location of Customer Entity | Region | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Mainland China | 38,903 | 56,624 | | United States | 147,675 | 121,990 | | Japan | 10,457 | 2,573 | | Europe | 37,945 | 5,551 | | Others | 18,787 | 10,719 | | Total | 253,767 | 197,457 | Non-current Assets by Location of Assets | Region | June 30, 2025 (RMB thousands) | December 31, 2024 (RMB thousands) | | :--- | :--- | :--- | | Mainland China | 422,311 | 418,599 | | Overseas | 63,099 | 58,326 | | Total | 485,410 | 476,925 | Major Customer Revenue Contribution | Customer | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Customer A | 99,352 | 66,531 | | Customer B | 30,468 | 1,162 | [Revenue](index=19&type=section&id=%E6%94%B6%E5%85%A5) Revenue primarily derives from CRDMO services, dominated by the Fee-for-Service (FFS) model, with most revenue recognized at a point in time Revenue by Type of Goods and Services | Type | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | CRDMO Services | 253,767 | 197,240 | | Others | – | 217 | | Total | 253,767 | 197,457 | Revenue by Type of Charging Model | Type | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Fee-for-Service (FFS) | 232,924 | 192,944 | | Full-Time Equivalent (FTE) | 20,843 | 4,296 | | Others | – | 217 | | Total | 253,767 | 197,457 | Revenue by Timing of Revenue Recognition | Type | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Services and goods transferred at a point in time | 232,924 | 192,944 | | Services transferred over a period of time | 20,843 | 4,513 | | Total | 253,767 | 197,457 | [Other Income and Gains](index=20&type=section&id=%E5%85%B6%E4%BB%96%E6%94%B6%E5%85%A5%E5%8F%8A%E6%94%B6%E7%9B%8A) Other income and gains primarily include government grants and bank interest income, with a decrease in total during the reporting period mainly due to a one-off government grant in 2024 Analysis of Other Income and Gains | Item | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Government grants – income | 4,940 | 29,682 | | Government grants – assets | 3,111 | – | | Bank interest income | 8,609 | 6,702 | | Net exchange differences | – | 3,678 | | Fair value gain on financial assets at fair value through profit or loss | 170 | 2,701 | | Others | 159 | 94 | | Total | 16,989 | 42,857 | [Income Tax](index=20&type=section&id=%E6%89%80%E5%BE%97%E7%A8%85) The company and its subsidiaries pay income tax at different rates in Mainland China, Hong Kong, and the US, with Mainland China subsidiaries enjoying preferential tax rates as high-tech enterprises - The corporate income tax rate in Mainland China is **25%**, with Medtide Bio-Pharmaceutical Co., Ltd. enjoying a preferential tax rate of **15%** as a high-tech enterprise (2024 to 2026)[72](index=72&type=chunk) - Hong Kong subsidiaries are subject to profits tax at **8.25%** on the first **HKD 2,000,000** of assessable profits and **16.5%** on the remaining profits, with no Hong Kong profits tax provision for the reporting period[74](index=74&type=chunk) - The US subsidiary is subject to a federal corporate income tax rate of **21%** and a California state income tax rate of **8.84%**[75](index=75&type=chunk) Income Tax Expense Breakdown | Item | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Current – Mainland China | 14,679 | 6,867 | | Current – United States | 505 | 500 | | Deferred | (1,506) | 578 | | Total | 13,678 | 7,945 | [Dividends](index=21&type=section&id=%E8%82%A1%E6%81%AF) For the six months ended June 30, 2025 and 2024, the company neither declared nor paid any dividends - For the six months ended June 30, 2025 and 2024, the company neither declared nor paid any dividends[77](index=77&type=chunk) [Earnings Per Share Attributable to Owners of the Parent](index=21&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E6%99%AE%E9%80%9A%E8%82%A1%E6%AC%8A%E7%9B%8A%E6%8C%81%E6%9C%89%E4%BA%BA%E6%87%89%E4%BD%B5%E6%AF%8F%E8%82%A1%E7%9B%88%E5%88%A9) Both basic and diluted earnings per share are calculated based on profit for the period attributable to owners of the parent and the weighted average number of shares outstanding, considering the dilutive effect of convertible bonds - Basic earnings per share are calculated based on the profit for the period attributable to owners of the parent and the weighted average number of ordinary shares outstanding[78](index=78&type=chunk) - Diluted earnings per share consider the fair value gain on convertible bonds and the dilutive effect of their assumed conversion into ordinary shares[78](index=78&type=chunk) Earnings Per Share Calculation | Item | 2025 (RMB thousands) | 2024 (RMB thousands) | | :--- | :--- | :--- | | Profit attributable to owners of the parent for basic EPS calculation | 101,999 | 50,567 | | Add: Fair value gain on convertible bonds | – | (10,781) | | Profit attributable to owners of the parent before fair value gain on convertible bonds | 101,999 | 39,786 | | Number of Shares (thousands) | 2025 | 2024 | | :--- | :--- | :--- | | Weighted average number of ordinary shares outstanding for basic EPS calculation | 125,000 | 125,000 | | Dilutive effect – weighted average number of ordinary shares: convertible bonds | – | 6,849 | | Total | 125,000 | 131,849 | [Trade and Bills Receivables](index=22&type=section&id=%E8%B2%A8%E6%98%93%E6%87%89%E6%94%B6%E6%AC%BE%E9%A0%85%E5%8F%8A%E6%87%89%E6%94%B6%E7%A5%A8%E6%93%9A) Total trade receivables decreased at the end of the reporting period, with the vast majority being receivables within one year Ageing Analysis of Trade Receivables | Ageing | June 30, 2025 (RMB thousands) | December 31, 2024 (RMB thousands) | | :--- | :--- | :--- | | Within 1 year | 32,498 | 57,460 | | 1 to 2 years | 350 | 240 | | 2 to 3 years | 3 | 20 | | Total | 32,851 | 57,720 | [Trade Payables](index=23&type=section&id=%E8%B2%A8%E6%98%93%E6%87%89%E4%BB%98%E6%AC%BE%E9%A0%85) Total trade payables increased at the end of the reporting period, primarily concentrated within one year and generally settled within one month Ageing Analysis of Trade Payables | Ageing | June 30, 2025 (RMB thousands) | December 31, 2024 (RMB thousands) | | :--- | :--- | :--- | | Within 1 year | 28,853 | 23,328 | | 1 to 2 years | 30 | 22 | | Over 2 years | 109 | 119 | | Total | 28,992 | 23,469 | - Trade payables are non-interest-bearing and generally settled within **one month**[81](index=81&type=chunk) [Share Capital](index=23&type=section&id=%E8%82%A1%E6%9C%AC) The company's share capital increased due to its initial public offering, with **16,800,000** ordinary shares issued Overview of Share Capital Changes | Item | Number of Shares | Amount (RMB thousands) | | :--- | :--- | :--- | | As at December 31, 2023, January 1, 2024 and December 31, 2024 | 125,000,000 | 125,000 | | Shares issued upon initial public offering | 16,800,000 | 16,800 | | As at June 30, 2025 | 141,800,000 | 141,800 | - As of June 30, 2025, the company issued a total of **16,800,000** ordinary shares through a global offering at a price of **HKD 30.60** per share[83](index=83&type=chunk) [Corporate Governance and Other Information](index=24&type=section&id=%E4%BC%81%E6%A5%AD%E7%AE%A1%E6%B2%BB%E5%8F%8A%E5%85%B6%E4%BB%96%E8%B3%87%E6%96%99) This section outlines the company's adherence to corporate governance standards, securities trading policies, and other relevant information for the reporting period [Compliance with Corporate Governance Code](index=24&type=section&id=%E9%81%B5%E5%AE%88%E4%BC%81%E6%A5%AD%E7%AE%A1%E6%B2%BB%E5%AE%88%E5%89%87) The company has complied with the Corporate Governance Code since its listing date, except for the combined roles of Chairman and CEO, which the Board believes ensures consistent leadership without compromising power balance - The company has complied with all applicable code provisions of the Corporate Governance Code since its listing date, except for the combined roles of Chairman and Chief Executive Officer[84](index=84&type=chunk)[85](index=85&type=chunk) - The Board believes that Dr. Xu Qi's dual role as Chairman and CEO ensures consistent leadership within the Group and enhances efficiency in strategic planning[85](index=85&type=chunk) [Standard Code for Securities Transactions by Directors and Supervisors of Listed Issuers](index=24&type=section&id=%E4%B8%8A%E5%B8%82%E7%99%BC%E8%A1%8C%E4%BA%BA%E8%91%A3%E4%BA%8B%E5%8F%8A%E7%9B%A3%E4%BA%8B%E9%80%B2%E8%A1%8C%E8%AD%89%E5%88%B8%E4%BA%A4%E6%98%93%E7%9A%84%E6%A8%99%E6%BA%96%E5%AE%88%E5%89%87) The company has adopted the Standard Code as the code of conduct for directors and supervisors trading company securities, with all directors and supervisors confirming strict compliance - The company has adopted the Standard Code as the code of conduct for directors and supervisors dealing in the company's securities[86](index=86&type=chunk) - All directors and supervisors confirmed strict compliance with the Standard Code from the listing date up to the date of this announcement[86](index=86&type=chunk) [Purchase, Sale or Redemption of the Company's Listed Securities](index=25&type=section&id=%E8%B3%BC%E8%B2%B7%E3%80%81%E5%87%BA%E5%94%AE%E6%88%96%E8%B4%96%E5%9B%9E%E6%9C%AC%E5%85%AC%E5%8F%B8%E4%B8%8A%E5%B8%82%E8%AD%89%E5%88%B8) From the listing date to the date of this announcement, neither the company nor any of its subsidiaries purchased, sold, or redeemed any of the company's listed securities - From the listing date up to the date of this announcement, neither the company nor any of its subsidiaries purchased, sold, or redeemed any of the company's listed securities[87](index=87&type=chunk) - As of June 30, 2025, the company did not hold any treasury shares[87](index=87&type=chunk) [Audit Committee](index=25&type=section&id=%E5%AF%A9%E6%A0%B8%E5%A7%94%E5%93%A1%E6%9C%83) The company has established an Audit Committee, comprising three members, responsible for reviewing financial reporting procedures, internal control systems, and connected transactions, and has reviewed these interim financial statements - The Audit Committee comprises three members: Mr. Xia Xinsheng (Chairman), Dr. Yu Changhai, and Dr. Zhu Xun[88](index=88&type=chunk) - Its primary responsibilities include reviewing and overseeing the Group's financial reporting procedures and internal control systems, and reviewing and approving connected transactions[88](index=88&type=chunk) - The Audit Committee has reviewed the Group's unaudited condensed consolidated financial statements for the six months ended June 30, 2025[88](index=88&type=chunk) [Significant Events After Reporting Period](index=25&type=section&id=%E5%A0%B1%E5%91%8A%E6%9C%9F%E5%BE%8C%E9%87%8D%E5%A4%A7%E4%BA%8B%E9%A0%85) From June 30, 2025, to the date of this announcement, there have been no significant events that could affect the company - From June 30, 2025, to the date of this announcement, there have been no significant events that could affect the company[89](index=89&type=chunk) [Interim Dividend](index=26&type=section&id=%E4%B8%AD%E6%9C%9F%E8%82%A1%E6%81%AF) The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025 - The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025[90](index=90&type=chunk) [Publication of Interim Results Announcement and Interim Report](index=26&type=section&id=%E5%88%8A%E7%99%BC%E4%B8%AD%E6%9C%9F%E6%A5%AD%E7%B8%BE%E5%85%AC%E5%91%8A%E5%8F%8A%E4%B8%AD%E6%9C%9F%E5%A0%B1%E5%91%8A) This interim results announcement has been published on the HKEX and company websites, and the interim report will be published and dispatched to shareholders in due course - This interim results announcement is published on the HKEX website www.hkexnews.hk and the company's website https://medtideinc.com/[91](index=91&type=chunk) - The Group's interim report for the six months ended June 30, 2025, will be published and dispatched to shareholders in due course[91](index=91&type=chunk) [Acknowledgements](index=26&type=section&id=%E8%87%B4%E8%AC%9D) The Board extends its sincere gratitude to the Group's shareholders, management team, employees, business partners, and clients for their support and contributions - The Board extends its sincere gratitude to the Group's shareholders, management team, employees, business partners, and clients[92](index=92&type=chunk) [By Order of the Board](index=26&type=section&id=%E6%89%BF%E8%91%A3%E4%BA%8B%E6%9C%83%E5%91%BD) This announcement is issued by Dr. Xu Qi, Chairman and CEO, on behalf of the Board, and lists the updated roster of the company's executive, non-executive, and independent non-executive directors - This announcement is issued by Dr. Xu Qi, Chairman and CEO, on behalf of the Board[93](index=93&type=chunk) - The company's executive directors include Dr. Xu Qi, Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao, and Ms. Li Lingmei[94](index=94&type=chunk) - The company's non-executive director is Mr. Wu Yihui; independent non-executive directors are Dr. Yu Changhai, Dr. Zhu Xun, and Mr. Xia Xinsheng[94](index=94&type=chunk)

据招股书数据，泰德医药近几年营收分别为3.51亿元、3.37亿元和4.42亿元，展现出强劲势头。其背后 是多元化的客户结构与全球化布局的支撑，目前，企业客户覆盖全球50多个国家，美国、中国内地、日 本和欧洲的营收分别占比55%、21.4%、7.1%和11%。较为分散的市场分布有效对冲了依靠单一市场的 风险。 本文源自：智通财经网 智通财经获悉，泰德医药(03880)早盘涨超9%，高见40.54港元，刷新上市新高。截至发稿，涨8.9%，报 40.14港元，成交额2103.22万港元。 消息面上，泰德医药将于8月29日召开董事会会议以审批中期业绩。根据弗若斯特沙利文的资料，于 2023年，按销售收入计，泰德医药是全球第三大专注于多肽的CRDMO，市场份额为1.5%。公司提供从 早期发现、临床前研究及临床开发以至商业化生产的全周期服务。全球专注于多肽的CRDMO市场的两 大参与者占23.8% 的市场份额，其余市场参与者则较为分散，2023年第三至六大参与者(包括本公司)分 别仅占约1%的市场份额。 ...

Core Viewpoint - 泰德医药's stock price increased over 9%, reaching a new high of 40.54 HKD, driven by positive market sentiment ahead of its upcoming board meeting to approve mid-term results [1] Company Summary - 泰德医药 is the third largest global player in the peptide-focused CRDMO market, holding a market share of 1.5% as of 2023, according to Frost & Sullivan [1] - The company offers a full-cycle service from early discovery, preclinical research, clinical development to commercial production [1] - The top two players in the global peptide-focused CRDMO market account for 23.8% of the market share, while the remaining participants, including 泰德医药, hold approximately 1% each [1] Financial Performance - 泰德医药's revenue for the past few years has shown strong momentum, with figures of 351 million, 337 million, and 442 million CNY [1] - The company's diverse client base and global presence support its growth, with clients across over 50 countries [1] - Revenue distribution is as follows: 55% from the United States, 21.4% from mainland China, 7.1% from Japan, and 11% from Europe, indicating a well-distributed market presence that mitigates risks associated with reliance on a single market [1]